Nationalistic behavior by governments may exclude some countries from access to COVID-19 vaccines. This could cost the world economy up to $1.2 trillion a year in GDP. A globally coordinated effort to fight the pandemic is key, not only from a public health perspective but also an economic one.
In this video conversation, Jennifer Bouey discusses RAND's rapid COVID-19 response, including insights and analysis to help strengthen and safeguard communities, rethink and retool institutions, and determine the best ways forward.
We conducted a mixed-methods study that involved focus group interviews and an online survey disseminated to a random group of licensed U.S. physicians, which oversampled physicians with a preexisting waiver to prescribe buprenorphine.
Vaccine development is only one part of the challenge in creating an immunization campaign to stop the pandemic. Once a safe and effective COVID-19 vaccine is ready, liability and compensation issues could affect its distribution and administration.
This study will evaluate whether the adapted intervention, also known as integrating support persons into recovery, is effective in increasing patient retention on buprenorphine when compared to usual care.
Although use of telemedicine for the treatment of opioid use disorders is growing, there is limited research on how it is actually being deployed in treatment. We explored how health centers across the U.S. are using it.
It is not uncommon to see a co-occurrence of PTSD and heavy use of substances, which can rise to the level of a substance use disorder. It may be necessary to challenge how the needs of veterans are addressed to remove barriers to care that make treating these co-occurring disorders simultaneously so difficult.
We conducted a scoping review that assessed the current state of evidence on EBP financing strategies for behavioral health. We defined financing strategies as techniques that secure and direct financial resources to support evidence-based practice implementation.
RAND Europe's Sonja Marjanovic explains how changes in society have brought about opportunities for the pharmaceutical industry to innovate to better meet the needs of patients and health care systems.
In this cross-sectional study with random assignment of clinicians and simulated-patient callers, many women, especially pregnant women, faced barriers to accessing treatment. Given the high out-of-pocket costs and lack of acceptance of insurance among many clinicians, access to affordable opioid use disorder treatment is a significant concern.
This cross-sectional study examines the number of patients prescribed buprenorphine by waivered-clinicians. Evidence shows waivered-clinicians who are able to prescribe buprenorphine treat fewer patients than their limit allows. With so much unmet demand for OUD treatment, this suggests the need for ongoing efforts to address treatment barriers.
Despite lacking the tools and resources to address the underlying causes of homelessness, police are constantly under pressure from business leaders and communities to “fix” it. Some law enforcement agencies are trying new approaches, but they need support to improve these efforts.
The increasingly positive news on COVID-19 vaccine development is also bringing growing alarm over whether Americans will trust these vaccines when they become available. While we were clearly not prepared for this virus, we now need to understand how we are going to roll out any proven vaccine.
Police have expressed frustration with being expected to handle complex social problems such as homelessness and substance use. Budgeting less money for police and more for other public safety strategies might appeal to law enforcement if these efforts relieve some of the unrealistic expectations on them.
China, one of the world's largest producers of vaccines, could be among the first to produce one for COVID-19. If that happens, then would China be able to produce sufficient doses for domestic use? And which other countries would likely benefit?